Production of Diphtheria Antitoxin: A Step-by-Step Guide | Pharmaceutical Sciences

Added:

Recombinant Monoclonal Antibodies and Animal-Free Production

While the traditional production of diphtheria antitoxin relies on immunizing animals (typically horses) and harvesting their plasma, this method faces significant ethical and clinical criticisms. Animal welfare advocates oppose the large-scale exploitation of horses for serum production. From a medical standpoint, animal-derived antitoxins carry a high risk of adverse immune reactions in humans, such as serum sickness and anaphylaxis, due to the presence of foreign proteins. Consequently, modern pharmaceutical research advocates for a shift toward recombinant DNA technology and the development of humanized monoclonal antibodies produced in vitro. These synthetic alternatives offer a standardized, safer, and cruelty-free method for neutralizing diphtheria toxin without the risks associated with animal-derived sera.

Fundamentals of immunology, including the concepts of antigens, antibodies, and the humoral immune response.
Pathophysiology of Corynebacterium diphtheriae, specifically how diphtheria toxin acts as an exotoxin to cause systemic disease.
The fundamental differences between active immunity (vaccines) and passive immunity (antisera/antitoxins).
Basic biochemical separation techniques, such as centrifugation, precipitation, and protein purification.
Quality control, potency testing (in vivo and in vitro), and safety evaluation of biological products.
Clinical applications of diphtheria antitoxin, including dosing protocols and the management of hypersensitivity reactions like serum sickness.
Modern biopharmaceutical alternatives, such as the development of recombinant humanized monoclonal antibodies to replace equine-derived sera.
Regulatory pathways and Good Manufacturing Practices (GMP) specific to the production of animal-derived biologics.
3.1K views66likes20:07@DrHARIHARANAG-Pharma-LectureOriginal Release: 2020-06-21

Diphtheria antitoxin is produced through a multi-step process involving horse immunization with diphtheria toxoid, followed by blood collection, serum processing, and refinement to isolate the beta-globulin fraction containing the antitoxin antibodies; the process includes animal selection (horses preferred for sufficient blood yield), quarantine for disease screening, gradual toxoid immunization with increasing doses, blood withdrawal from the jugular vein, serum separation through centrifugation, and purification using either fractional precipitation with ammonium sulfate or proteolytic digestion with pepsin to remove unwanted proteins and obtain pure antitoxin for passive immunization against diphtheria toxin.